SMMT · Summit Therapeutics Inc.

Oncology biotech betting on ivonescimab challenging Keytruda in lung cancer

Risiko 8/10 · HIGH · binary data · $12.55 ▼ 4.24%

Kennzahlen

• Price $12.55
• Market cap $10.0B
• P/E (ttm) n/a
• Div yield none
• 52-wk range $12.25 – $30.98

Wichtigste Risiken

• Binary readout risk on key Phase 3 trials (Shareholders) — EXTREME
• Stretched valuation vs. pre-approval status (New buyers) — EXTREME
• Reliance on China-derived data for US/EU filing (Regulatory) — HIGH
• Funding/dilution for global trial program (Existing holders) — HIGH

Fazit

A high-flying oncology bet with genuine blockbuster potential and equally genuine binary risk on whether its data holds up in Western trials.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.